Cullinan Therapeutics, Inc. (CGEM) SEC Filings

Cullinan Therapeutics, Inc. (CGEM) officer Jennifer Michaelson has notified of a planned sale of 8,000 shares of common stock through Morgan Stanley Smith Barney, with an aggregate market value of $176,720.00 based on a per-share price of $64.354694 as of September 8, 2026.

The shares relate to equity awards and purchases, including stock options, restricted stock units, and employee stock purchase plan shares, and follow prior sales in recent months under a Rule 10b5-1 trading arrangement.

Cullinan Therapeutics Chief Scientific Officer Jennifer Michaelson exercised 30,000 stock options for Common Stock at an exercise price of $4.30 per share, then sold 30,000 Common Shares at a weighted average price of $20.26 per share pursuant to a Rule 10b5-1 trading plan adopted on August 7, 2025. The options exercised were from a grant that vested 25% on July 4, 2020, with the remainder vesting in 36 monthly installments, and she continues to hold 82,987 stock options of this series directly, expiring on October 28, 2030.

Biotechnology Value Fund and affiliated entities report significant ownership of Cullinan Therapeutics, Inc. common stock. As of June 30, 2026, the group, including a managed account, beneficially owns 6,491,123 shares of common stock, representing approximately 9.99% of the outstanding shares.

The position includes 204,209 shares of Series A convertible preferred stock, which are convertible into 2,042,090 common shares at a 10:1 ratio. A 9.99% “Conversion Blocker” currently limits conversion to 740,440 of these underlying shares. Individual vehicles BVF and BVF2 hold approximately 5.7% and 3.5% of the class, respectively, with shared voting and dispositive power allocated among the BVF entities and Mark N. Lampert as described.

T. Rowe Price Associates, Inc., organized in Maryland, reports beneficial ownership of 3,825,950 shares of Cullinan Therapeutics Inc common stock. This position represents 6.2% of the class as of the reporting date. The firm reports sole voting power and sole dispositive power over all 3,825,950 shares, with no shared voting or dispositive power. T. Rowe Price Associates states that this report should not be construed as an admission that it is the beneficial owner of these securities, and it expressly denies such beneficial ownership.

A shareholder of the company with symbol CGEM has indicated an intent to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on August 13, 2026 on NASDAQ, in connection with a cash exercise of stock options. The disclosure also lists prior 10b5-1 sales for Jennifer Michaelson of 8,000 shares of common stock on July 6, 2026 for $142,586.

Cullinan Therapeutics reported that the global Phase 3 REZILIENT3 trial in previously untreated, locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations met its primary endpoint of progression-free survival at a planned interim analysis. The combination of zipalertinib plus platinum-based chemotherapy showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy alone, with manageable observed safety, leading the Independent Data Monitoring Committee to recommend unblinding. The study, which enrolled 285 adults, will continue to monitor efficacy and safety, with full results to be presented at a future medical conference. Based on these topline results, Cullinan and its partner Taiho plan, after discussions with the U.S. Food and Drug Administration, to pursue U.S. regulatory approval for zipalertinib plus chemotherapy as a first-line treatment option for this genetically defined subset of NSCLC.

State Street Corporation reported beneficial ownership of common stock of Cullinan Therapeutics Inc. on a Schedule 13G. State Street beneficially owns 3,668,627 shares of common stock, representing 6% of the class. These shares are held with shared voting power over 3,565,748 shares and shared dispositive power over 3,668,627 shares, with no sole voting or dispositive power. The filing attributes the holdings to asset management subsidiaries including SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd.

Cullinan Therapeutics, Inc. reported a Q2 2026 net loss of $53.7 million, improving from $70.1 million a year earlier, driven by lower R&D and G&A spending. Research and development expenses were $44.4 million in the quarter and $86.6 million for the first half of 2026.

Cash, cash equivalents and short-term investments totaled $334.5 million as of June 30, 2026, with an additional $21.4 million in long-term investments and interest receivable, which management expects to fund operations for at least 12 months. The company continues to invest in its T cell engager pipeline, including CLN-978 for autoimmune diseases, velinotamig for autoantibody-driven disorders and CLN-049 for AML and MDS.

For zipalertinib, co-developed with Taiho, the U.S. FDA accepted a new drug application for previously treated EGFR exon 20 insertion NSCLC and set a February 27, 2027 action date, with additional Phase 3 data expected by year-end 2026. Cullinan also plans potentially registrational Phase 2 trials for CLN-049. The company notes it will become a large accelerated filer in 2027, which will increase compliance and reporting requirements.

Cullinan Therapeutics reported second‑quarter 2026 results and outlined multiple near‑term clinical catalysts. For CLN‑978 in SLE and RA, additional multi‑dose data are planned in Q4 and Q3 2026, with Phase 2 expansion studies targeted for early 2027, including lupus nephritis and difficult‑to‑treat RA.

Velinotamig showed early complete renal responses in two SLE nephritis patients in a China study, with more data expected Q4 2026 and a global Phase 1/2 basket trial in autoimmune cytopenias planned for early 2027. Following a positive End‑of‑Phase 1 FDA meeting, a potentially registrational Phase 2 CLN‑049 study in relapsed/refractory AML is expected to start in Q3 2026, alongside a planned AML combination trial in Q4 2026. Zipalertinib’s NDA for EGFR ex20ins NSCLC has a PDUFA date of February 27, 2027, with Cullinan eligible for up to $130 million in U.S. approval milestones and a 50/50 U.S. profit share.

Financially, cash and investments were $356 million as of June 30, 2026, which management expects to fund operations into 2029. Q2 2026 research and development expenses were $44.4 million and general and administrative expenses were $12.8 million, leading to a net loss of $53.7 million, compared with $70.1 million a year earlier.